U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07012694) titled '22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions' on May 25.
Brief Summary: The investigators conduct a prospective, multicenter, blinded, randomized controlled trial to compare the diagnostic value and safety of the 22G Adapt needle versus the 22G Franseen needle for histopathological evaluation of solid lesions.
Study Start Date: June 10
Study Type: INTERVENTIONAL
Condition:
Pancreatic Neoplasms
Mediastinal Neoplasms
Abdominal Neoplasm, Excluding Pancreas Neoplasm
Intervention:
DEVICE: 22G Franseen Needle Group
Fine-needle-biopsy (22G Franseen, Boston Scientific, Winston-Salem, USA)...